Editing
Peptide design guideline
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
*As many features and their combinations affect immunogen design, machine-learning approaches and protein 3D structure/informatics-based programmes are used to design peptide immunogens. *[[UniprotKB|UniprotKB]] provides essential information on protein function, structure and properties. *Establish domain regions. Domains will be present in other proteins and should be avoided in the sequence of the immunogen as they might increase cross reactivity. *'''Avoid''' complex and inaccessible regions such as '''alpha helices''' and'''beta sheets'''. Instead aim for accessible regions of the native protein which are '''surface-exposed, hydrophilic and flexible'''. *Epitopes (antigenic determinants) are preferably located at'''β turns or loops with amphipathic helices.''' The C- and N-termini of proteins are often surface-exposed with a high degree of flexibility. *Peptide length in general 10–20 amino acids. A long peptide increases immunogenicity, but also increases the chance for cross-reactivity while a short peptide improves the specificity, but may not be immunogenic. *'''Avoid long chains of hydrophobic residues.''' Peptide solubility can be improved by changing the peptide length and/or adding 1–2 hydrophilic amino acid residues to the N- or C-terminus. *'''Avoid N-terminal glutamine or aspargine and C-terminal proline or glycine i'''n a peptide. *'''Avoid internal cysteine, which can be replaced with serine'''. *A'''void multiple (more than three) serine or proline residues i'''n a sequence. Also '''avoid multiple glutamine residues''' as this can result in hydrogen bonding between peptides. *Conservative residues can be used to replace any undesirable residues to improve peptide properties. *'''Avoid tripeptide arginine-glycine (RGD motif)''', small molecule binding sites, biologically active regions and post-translational modification site(s) as they may mask the antibody recognition site. *A terminal cysteine may be added to the peptide sequence to allow peptide conjugation to carrier proteins. It is added away from the epitope location if known. If the peptide is derived from the N-terminus of the protein the cysteine should be added to the C-terminus of the peptide and vice-versa. *Peptide Purity For antibody generation and testing, peptide purity > 70% is enough, however, for biological activity studies, peptide purity > 95% is required. *Peptide Amino Acid Composition Amino acid composition governs every aspect of the peptide’s functionality. Peptide antigens should be designed to contain sequences that are found on the '''surface of the native protein'''. '''Both hydrophobic and hydrophilic residues should be included'''. In particular, it is favorable for the peptide sequence to incorporate amino acids that are antigenic. On the other hand, '''Cysteine, methionine, and tryptophan are susceptible to oxidation and side reactions'''. Peptides containing multiple instances of these residues are also difficult to be obtained in high purity. Sometimes, the peptides are chemically modified or conjugated with specific ligands for desired properties, such as solubility, stability, even purification methods. Additional modifications such as N- and C-termini capping, spacer insertions and amino acid replacement are also performed. *Peptide Length Peptide length is a critical factor to consider when synthesizing peptide. The longer the peptide sequence, the more difficult for their synthesis and purification. Longer peptides generally have lower crude peptide purity. Peptide antigens'length to cover 10-15 residues for antibody production. *Peptide Solubility Hydrophobicity of each constituted amino acids strongly influences the corresponding peptide’s solubility. By changing the frequency of occurrence of hydrophobic and hydrophilic amino acids, Peptides with high incidences of hydrophobic amino acids including'''tryptophan, leucine, valine, methionine, phenylalanine, and isoleucine may not easily dissolve in aqueous solutions'''. '''Hydrophobic amino acid content is suggested to be kept below 50%'''.At least one charged residue should be incorporated within every five amino acids. At physiological pH, arginine, glutamine, aspartic acid, and lysine all have charged side chains. '''A single conservative replacement or addition of polar residues to the N- or C-terminus may also improve peptide solubility.''' *Secondary Structure During peptide synthesis, beta sheet formation can cause incomplete solvation of the growing peptide, which results in a high incidence of deletion sequences in the final product. '''Avoid multiple or adjacent residues of valine, isoleucine, tyrosine, phenylalanine, tryptophan, leucine, glutamine, or threonine to prevent beta sheet formation'''. If the above recommendation cannot be implemented practically, conservative replacement may help by reinserting a glycine or proline at every third residue or replacing glutamine with asparagine, or threonine with serine. [[Category:Antibodies]]
Summary:
Please note that all contributions to ELN may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
ELN:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
View history
More
Search
Navigation
Category:
Main page
To Do
Tasks
My ELN
Weekly Reports
Buffer Recipe
SOP
Protocols
Inventories
Projects
Products
Customers
Contacts
Suppliers
Vectors
Vector Map
Clones
Cloning
Sequencing
NGS
Protein Expression
Purchaseing
QC
293 Expression
CHO Expression
Sf9 Expression
Protein Purification
Stem Cells
Cytokines
Protein Kinases
GPCR
Cell Lines
Competent Cells
Viral Proteins
VLP
Baculovirus
AAV
Adenovirus
Lentivirus
Virus Titering
Antibodies
Transfection
ELISA
qPCR RT-PCR
ImmunoAssay
Multiplex BioAssa
Lateral_Flow
Conjugation
Compounds Synthesis
BioEngineering
GenomeEngineering
Services
Software
Ideas
Links
Knowledgebase
Employees
Company
Tools
What links here
Related changes
Page information
Navigation
Special pages